Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Modipafant

Drug Profile

Modipafant

Alternative Names: 60P 002; UK 80067

Latest Information Update: 28 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Developer 60 Degrees Pharmaceuticals Australia; Pfizer
  • Class Antiasthmatics; Dihydropyridines; Imidazoles; Small molecules
  • Mechanism of Action Calcium channel antagonists; Platelet activating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Dengue
  • Discontinued Asthma

Most Recent Events

  • 28 Oct 2018 No recent reports of development identified for phase-I development in Dengue in USA
  • 14 May 2018 60 Degree Pharmaceuticals plans a phase II trial for Dengue (60 Degrees pipeline, May 2018)
  • 11 Dec 2015 Modipafant licensed to Knight Therapeutics in Canada, Israel and Russia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top